HUP0400229A2 - Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények - Google Patents

Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400229A2
HUP0400229A2 HU0400229A HUP0400229A HUP0400229A2 HU P0400229 A2 HUP0400229 A2 HU P0400229A2 HU 0400229 A HU0400229 A HU 0400229A HU P0400229 A HUP0400229 A HU P0400229A HU P0400229 A2 HUP0400229 A2 HU P0400229A2
Authority
HU
Hungary
Prior art keywords
general formula
formula
triazaspiro
same
active ingredient
Prior art date
Application number
HU0400229A
Other languages
English (en)
Inventor
Hiromu Habashita
Shin-Ichi Hamano
Shiro Shibayama
Yoshikazu Takaoka
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of HUP0400229A2 publication Critical patent/HUP0400229A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)

Abstract

A találmány tárgyát (I) általános képletű triaza-spiro[5.5]-undekánszármazékok, ezek kvaterner ammónium sói, N-oxidjai és nemtoxikus sóiés ezeket hatóanyagként tartalmazó gyógyszerkészítmények képezik (ahola képletben R1 jelentése (II) vagy (III) általános képletűszubsztituens; R2 jelentése alkil-, alkinil vagy hasonló csoport; R3és R4 jelentése hidrogénatom, adott esetben szubsztituált alkilcsoportvagy hasonló csoport, vagy R3 és R4 együtt (IV) általános képletűcsoportot képeznek; és R5 jelentése hidrogénatom vagy alkilcsoport. Az(I) általános képletű vegyületek a kemokin/kemokin receptor hatásátszabályozzák, és különböző gyulladásos betegségek, asztma, atopikusdermatitisz, csalánkiütés, allergiás bélbetegségek, vesegyulladás,nefropátia, hepatitisz, artritisz, reumatoid artritisz és hasonlóbetegségek megelőzésére és kezelésére szolgáló gyógyszerkészítményekhatóanyagaiként alkalmazhatók. Ó
HU0400229A 2001-03-19 2002-03-18 Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények HUP0400229A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001079610 2001-03-19
JP2001160251 2001-05-29
PCT/JP2002/002554 WO2002074770A1 (fr) 2001-03-19 2002-03-18 Derives de triazaspiro[5.5]undecane et medicaments les contenant en tant que principe actif

Publications (1)

Publication Number Publication Date
HUP0400229A2 true HUP0400229A2 (hu) 2004-08-30

Family

ID=26611613

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400229A HUP0400229A2 (hu) 2001-03-19 2002-03-18 Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények

Country Status (23)

Country Link
US (2) US7053090B2 (hu)
EP (2) EP1619194A3 (hu)
JP (1) JP3558079B2 (hu)
KR (1) KR100714154B1 (hu)
CN (1) CN1291988C (hu)
AT (1) ATE328884T1 (hu)
AU (1) AU2002238947B2 (hu)
BR (1) BR0208167A (hu)
CA (1) CA2440264A1 (hu)
CZ (1) CZ20032531A3 (hu)
DE (1) DE60212110T2 (hu)
DK (1) DK1378510T3 (hu)
ES (1) ES2266452T3 (hu)
HU (1) HUP0400229A2 (hu)
IL (1) IL157819A0 (hu)
MX (1) MXPA03008529A (hu)
NO (1) NO20034148L (hu)
NZ (1) NZ528249A (hu)
PL (1) PL364427A1 (hu)
PT (1) PT1378510E (hu)
RU (1) RU2269528C2 (hu)
TW (1) TWI254047B (hu)
WO (1) WO2002074770A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285552B2 (en) * 2001-03-19 2007-10-23 Ono Pharmaceuticals Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
AU2003271057A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
JPWO2004026873A1 (ja) * 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
AU2003296992A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
JPWO2004054616A1 (ja) * 2002-12-13 2006-04-20 小野薬品工業株式会社 ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
JPWO2004094424A1 (ja) * 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
TW200616968A (en) 2004-08-27 2006-06-01 Ono Pharmaceutical Co Compound having basic substituent and application thereof
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
EP1852432A4 (en) * 2005-02-25 2010-04-14 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE
US7872024B2 (en) 2005-04-20 2011-01-18 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
AU2006240248A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
EP1874295A4 (en) 2005-04-20 2009-08-12 Merck & Co Inc benzothiophene
JPWO2006129679A1 (ja) * 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
AU2007225836A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
JP2009535333A (ja) 2006-04-26 2009-10-01 メルク エンド カムパニー インコーポレーテッド 二置換アニリン化合物
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
JP2009544611A (ja) 2006-07-20 2009-12-17 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2692153A1 (en) 2007-06-27 2009-01-08 Richard W. Heidebrecht, Jr. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
RU2455284C1 (ru) * 2011-03-15 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Способ получения 5-арил-2-метил-1,3-диоксо-2-азаспиро[5,5]ундекан-4-карбонитрилов и средство, проявляющее анальгетическую активность
WO2020246487A1 (ja) * 2019-06-04 2020-12-10 第一三共株式会社 ジスピロジケトピペラジン構造を有する化合物
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998031364A1 (en) 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
US7285552B2 (en) * 2001-03-19 2007-10-23 Ono Pharmaceuticals Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient

Also Published As

Publication number Publication date
NO20034148D0 (no) 2003-09-17
KR20040008142A (ko) 2004-01-28
DK1378510T3 (da) 2006-10-16
NO20034148L (no) 2003-11-14
NZ528249A (en) 2005-03-24
TWI254047B (en) 2006-05-01
EP1378510B1 (en) 2006-06-07
JPWO2002074770A1 (ja) 2004-07-08
CN1518551A (zh) 2004-08-04
EP1378510A1 (en) 2004-01-07
RU2003128067A (ru) 2005-04-10
IL157819A0 (en) 2004-03-28
US20040082584A1 (en) 2004-04-29
DE60212110T2 (de) 2006-11-09
JP3558079B2 (ja) 2004-08-25
EP1378510A4 (en) 2004-09-29
KR100714154B1 (ko) 2007-05-07
EP1619194A2 (en) 2006-01-25
ES2266452T3 (es) 2007-03-01
RU2269528C2 (ru) 2006-02-10
US7053090B2 (en) 2006-05-30
CN1291988C (zh) 2006-12-27
MXPA03008529A (es) 2004-06-30
US7262193B2 (en) 2007-08-28
BR0208167A (pt) 2004-03-09
CA2440264A1 (en) 2002-09-26
AU2002238947B2 (en) 2007-10-18
US20050215557A1 (en) 2005-09-29
CZ20032531A3 (cs) 2004-01-14
EP1619194A3 (en) 2006-06-07
PL364427A1 (en) 2004-12-13
ATE328884T1 (de) 2006-06-15
WO2002074770A1 (fr) 2002-09-26
PT1378510E (pt) 2006-09-29
DE60212110D1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
HUP0400229A2 (hu) Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
NZ519183A (en) Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
HUP0202795A2 (hu) Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
NO20045461L (no) Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
HUP0301389A2 (hu) Purinszármazékok
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
NO20054763L (no) Salter av clopidogrel og fremgangsmate for fremstilling derav
HUP0000720A2 (hu) Imidazo [1,2-a] piridinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0828728T3 (da) Phenyldihydrobenzofuraner
ATE221064T1 (de) Cyclische amidderivate als neurokinin a antagonisten
ES2189871T3 (es) Ciclohexil-dihidro-benzofuranos.
DE69217511D1 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
MXPA03011563A (es) Derivados de benzoxazepina y su uso como estimuladores de receptor ampa.
ES8802310A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridinas
YU73200A (sh) 2-aminopiridini koji sadrže spojene ciklične supstituente kao inhibitori nitro oksid sintaze

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees